Autolus Therapeutics plc (F:6A3A) — Market Cap & Net Worth
Market Cap & Net Worth: Autolus Therapeutics plc (6A3A)
Autolus Therapeutics plc (F:6A3A) has a market capitalization of $361.95 Million (€309.60 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #14030 globally and #1415 in its home market, demonstrating a 1.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Autolus Therapeutics plc's stock price €1.33 by its total outstanding shares 266143286 (266.14 Million). Review 6A3A total debt and obligations to assess the company's total debt and financial obligations.
Autolus Therapeutics plc Market Cap History: 2018 to 2026
Autolus Therapeutics plc's market capitalization history from 2018 to 2026. Data shows change from $7.39 Billion to $413.83 Million (-29.24% CAGR).
Autolus Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Autolus Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.69x
Autolus Therapeutics plc's market cap is 6.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $7.39 Billion | $1.41 Million | -$44.75 Million | 5254.38x | N/A |
| 2019 | $3.61 Billion | $2.91 Million | -$123.85 Million | 1241.17x | N/A |
| 2020 | $2.18 Billion | $242.00K | -$142.09 Million | 9000.19x | N/A |
| 2021 | $1.34 Billion | $2.33 Million | -$142.10 Million | 574.22x | N/A |
| 2022 | $516.51 Million | $6.19 Million | -$148.84 Million | 83.39x | N/A |
| 2023 | $1.84 Billion | $1.70 Million | -$208.38 Million | 1081.14x | N/A |
| 2024 | $665.86 Million | $10.12 Million | -$220.66 Million | 65.80x | N/A |
| 2025 | $504.06 Million | $75.39 Million | -$287.53 Million | 6.69x | N/A |
Competitor Companies of 6A3A by Market Capitalization
Companies near Autolus Therapeutics plc in the global market cap rankings as of June 19, 2026.
Key companies related to Autolus Therapeutics plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Autolus Therapeutics plc Historical Marketcap From 2018 to 2026
Between 2018 and today, Autolus Therapeutics plc's market cap moved from $7.39 Billion to $ 413.83 Million, with a yearly change of -29.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €413.83 Million | -17.90% |
| 2025 | €504.06 Million | -24.30% |
| 2024 | €665.86 Million | -63.73% |
| 2023 | €1.84 Billion | +255.42% |
| 2022 | €516.51 Million | -61.40% |
| 2021 | €1.34 Billion | -38.57% |
| 2020 | €2.18 Billion | -39.66% |
| 2019 | €3.61 Billion | -51.18% |
| 2018 | €7.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Autolus Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $361.95 Million USD |
| MoneyControl | $361.95 Million USD |
| MarketWatch | $361.95 Million USD |
| marketcap.company | $361.95 Million USD |
| Reuters | $361.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more